Shares of Adamas Pharmaceuticals ADMS rose in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 22.89% over the past year to ($0.64), which missed the estimate of ($0.51).
Revenue of $21,010,000 rose by 28.52% from the same period last year, which beat the estimate of $20,960,000.
Looking Ahead
Adamas Pharmaceuticals Sees FY 2021 Total Operating Expenses Expenses $115M-$130M
How To Listen To The Conference Call
Date: Feb 23, 2021
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/9kbxdi2b
Technicals
52-week high: $9.15
Company's 52-week low was at $1.90
Price action over last quarter: Up 49.86%
Company Profile
Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.